Novel phosphorus-containing 17β-side chain mifepristone analogues as progesterone receptor antagonists

Steroids

Volumn 71, Issue 11-12, 2006, Pages 949-954

  Jiang, Weiqin ^a   Allan, George ^a   Chen, Xin ^a   Fiordeliso, James J ^a   Linton, Olivia ^a   Tannenbaum, Pamela ^a   Xu, Jun ^a   Zhu, Peifang ^a   Gunnet, Joseph ^a   Demarest, Keith ^a   Lundeen, Scott ^a   Sui, Zhihua ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

C 17 phosphorus containing steroids; Selective progesterone receptor antagonist

Indexed keywords

ANTIGESTAGEN; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; PHOSPHORUS; PROGESTERONE RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG DETERMINATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; CELL LINE; FEMALE; HORMONE ANTAGONISTS; HUMANS; MIFEPRISTONE; MOLECULAR STRUCTURE; PHOSPHORUS; PROGESTERONE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROGESTERONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750218230     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2006.07.003     Document Type: Article

References (19)

1. Spitz I.M., and Chwalisz K. Progesterone receptor modulators and progesterone antagonists in women's health. Steroids 65 (2000) 807-815
2. Teutsch G., and Philibert D. History and perspectives of antiprogestins from the chemist's point of view. Human Repro 9 Suppl. 1 (1994) 11-30
3. DaManno, Debroah, et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 68 (2003) 1019-1032
4. Zhang Z.M., et al. Molecular and pharmacological properties of a potent and selective novel non-steroidal progesterone receptor agonist Tanaproget. J Bio Chem 280 (2005) 28468-28475
5. Hess-Stumpp H., Hoffmann J., and Fuhrmann U. Progesterone receptor antagonist (antiprogestins). Drugs Future 27 (2002) 1113-1123
6. Ulmann A., Peyron R., and Silverstre L. Clinical uses of Mifepristone (MFP). Ann N Y Acad Sci 761 (1995) 248-260
7. Murphy A.A., Kettel L.M., Morales A.J., Roberts V.J., and Yen S.S. Regression of Uterine Leiomyomata in Response to the Antiprogesterone RU-486. J Clin Endo Metab 76 (1993) 513-517
8. Kettel L.M., Murphy A.A., Mortola J.F., Liu J.H., Ulmann A., and Yen S.S. Endocrine response to long-term administration of the antiprogesterone RU-486 in patients with pelvic endometriosis. Fertil Steril 56 (1991) 402-407
9. Kehler J., Ebert B., Dahl O., and Krogsgarrd-Larsen P. Syntheses and GABA receptor binding properties of 4-amino-1-,2-, and 3-hydroxybutylphosphinic acids. Tetrahedron 55 (1999) 771-780
10. Williams S.P., and Sigler P.B. Atomic structure of progesterone complexed with its receptor. Nature 393 (1998) 392-396
11. Kauppi B., Jacob C., Farnegardh M., Yang J., Ahola H., Alarcon M., et al. The three dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain. J Bio Chem 278 (2003) 22748-22754
12. Rao P.N., wang Z., Cessac J.W., Rosenberg R.S., Jenkins D.J.A., and Diamandis E.P. New 11β-aryl-substituted steroids exhibit both progestational and antiprogestational activity. Steroids 63 (1998) 523-530
13. 2]. A New Reagent Preparation Term Alkynes. Tet Lett 38 (1997) 8863-8866
14. Fensome A., Bender R., Cohen J., Collins M.A., Mackner V.A., Miller L.L., et al. New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles. Bio Med Chem Lett 12 (2002) 3487-3490
15. Fensome A., Koko M., Wrobel J., Zhang P., Zhang Z., Cohen J., et al. Novel 5-aryl-1,3-dihydro-indole-2-thiones: potent, orally active progesterone receptor agonists. Bio Med Chem Lett 13 (2003) 1317-1320
16. Zhang P., Terefenko E.A., Fensome A., Wrobel J., Winneker R., Lundeen S., et al. 6-aryl-1,4-dihydro-benzo[d][1,3]oxazin-2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists. J Med Chem 45 (2002) 4379-4382
17. Zhang P., Terefenki E.A., Fensome A., Wrobel J., Winneker R., and Zhang Z. Novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists. Bio Med Chem Lett 13 (2003) 1313-1316
18. Fensome A., Bender R., Chopra R., Cohen J., et al. Synthesis and SAR of novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective nonsteroidal PR agonist Tanaproget. J Med Chem 48 (2005) 5092-5095
19. Lundeen S.G., Zhang Z., Zhu Y., Carver J.M., and Winneker R.C. Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone. J Steroid Biochem Mol Biol 78 (2001) 137-143